Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
18 janv. 2022 08h00 HE
|
Levo Therapeutics, Inc.
CHICAGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related...
Healthcare Transportation Services Market Is In Demand With Growing Population - IndustryARC Research
20 mars 2017 15h30 HE
|
IndustryARC
Hyderabad, India, March 20, 2017 (GLOBE NEWSWIRE) -- The report “Healthcare Transportation Services Market Analysis: By Transportation Service Type (Medical Transportation, Non-Medical...